“Comprehensive Analysis of Factors Influencing Recurrence and Survival in Glioblastoma: Implications for Treatment Strategies”: A Single Center Study
Glioblastoma is a highly aggressive malignancy affecting the brain and central nervous system. It is the most common malignant primary brain tumor, yet its prognosis remains poor. Median survival typically ranges from around 13 months with standard treatment to up to 19.9 months in some recent clini...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Journal of Molecular Pathology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-5261/5/4/35 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846104179532103680 |
|---|---|
| author | Ahmed Bendari Sunder Sham Hamed Hammoud Oana Vele Brett Baskovich David Huang Alaa Bendari Rachel Saks Reham Al-Refai Tasneem Bendari Layth Kataw Fnu Kiran Fnu Anjali Sanjay Kirshan Kumar Manju Harshan |
| author_facet | Ahmed Bendari Sunder Sham Hamed Hammoud Oana Vele Brett Baskovich David Huang Alaa Bendari Rachel Saks Reham Al-Refai Tasneem Bendari Layth Kataw Fnu Kiran Fnu Anjali Sanjay Kirshan Kumar Manju Harshan |
| author_sort | Ahmed Bendari |
| collection | DOAJ |
| description | Glioblastoma is a highly aggressive malignancy affecting the brain and central nervous system. It is the most common malignant primary brain tumor, yet its prognosis remains poor. Median survival typically ranges from around 13 months with standard treatment to up to 19.9 months in some recent clinical trials. Despite advances in treatment, the aggressive nature of glioblastoma continues to present significant challenges for improving patient outcomes. This study aimed to analyze various biological, radiological, and molecular factors associated with glioblastoma recurrence and to estimate survival outcomes. A total of 104 glioblastoma patients diagnosed between January 2017 and September 2022 were included. Patient demographics, treatment received, and molecular characteristics were obtained from the Electronic Patient Record (EPR). Tumor molecular characteristics were analyzed using the OnkoSight Advanced CNS NGS panel. Statistical analyses were performed to develop a prognostic model for glioblastoma recurrence and estimate survival rates. Among the patients, 65.4% had no recurrence, with a mean age of 63 years. No gender or BMI differences were observed, but ages <60 years were associated with recurrence. Radiological findings showed no significant differences in tumor size, necrosis, site, or focality. In multivariate analysis, the female gender, obesity, old age (>60 years), or bifocal tumors were associated with decreased glioblastoma recurrence. However, factors like tumor site, size, necrosis, <i>MGMT</i> promoter methylation, and <i>EGFR</i> alteration showed no significant association with recurrence. Median survival was 12 months, with older age significantly associated with shorter survival. Tumor sizes >4 cm showed shorter survival trends but not statistically significantly. Patients who lived longer experienced more tumor recurrence incidents. Standard or non-standard treatments were associated with longer median survival compared to no treatment. Our findings provide insights into factors influencing glioblastoma recurrence and survival. Age, gender, and tumor characteristics play pivotal roles in recurrence. Understanding these factors could aid in optimizing treatment strategies and improving patient outcomes. However, further multicentric investigations are needed to validate these findings. This study emphasizes the importance of considering biological and radiological factors in clinical decision-making for glioblastoma cases. |
| format | Article |
| id | doaj-art-e66e3a1517a143a09cf3b5e461d44429 |
| institution | Kabale University |
| issn | 2673-5261 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Molecular Pathology |
| spelling | doaj-art-e66e3a1517a143a09cf3b5e461d444292024-12-27T14:32:58ZengMDPI AGJournal of Molecular Pathology2673-52612024-11-015452053210.3390/jmp5040035“Comprehensive Analysis of Factors Influencing Recurrence and Survival in Glioblastoma: Implications for Treatment Strategies”: A Single Center StudyAhmed Bendari0Sunder Sham1Hamed Hammoud2Oana Vele3Brett Baskovich4David Huang5Alaa Bendari6Rachel Saks7Reham Al-Refai8Tasneem Bendari9Layth Kataw10Fnu Kiran11Fnu Anjali12Sanjay Kirshan Kumar13Manju Harshan14Department of Pathology and Laboratory Medicine, Lenox Hill Hospital, New York, NY 10075, USADepartment of Pathology and Laboratory Medicine, Lenox Hill Hospital, New York, NY 10075, USAQatar Metabolic Institute, Hamad Medical Corporation, Doha 3050, QatarDepartment of Pathology and Laboratory Medicine, Lenox Hill Hospital, New York, NY 10075, USAMolecular Genetic Pathology Division, Mount Sinai Hospital, New York, NY 10029, USADepartment of Hematology and Medical Oncology, Lenox Hill Hospital, New York, NY 10075, USADepartment of Medical Biochemistry, Zagazig University, Zagazig 7120001, EgyptDepartment of Radiology, Lenox Hill Hospital, New York, NY 10075, USADepartment of Pathology and Laboratory Medicine, Lenox Hill Hospital, New York, NY 10075, USAZagazig University Hospital, Zagazig 7120001, EgyptDepartment of Pathology and Laboratory Medicine, Lenox Hill Hospital, New York, NY 10075, USADepartment of Pathology and Laboratory Medicine, Staten Island University Hospital, New York, NY 10305, USASakhi Baba General Hospital, Sukkur 06533, PakistanDepartment of Gastroenterology, Bahria University Health Sciences, Karachi 44000, PakistanDepartment of Pathology and Laboratory Medicine, Lenox Hill Hospital, New York, NY 10075, USAGlioblastoma is a highly aggressive malignancy affecting the brain and central nervous system. It is the most common malignant primary brain tumor, yet its prognosis remains poor. Median survival typically ranges from around 13 months with standard treatment to up to 19.9 months in some recent clinical trials. Despite advances in treatment, the aggressive nature of glioblastoma continues to present significant challenges for improving patient outcomes. This study aimed to analyze various biological, radiological, and molecular factors associated with glioblastoma recurrence and to estimate survival outcomes. A total of 104 glioblastoma patients diagnosed between January 2017 and September 2022 were included. Patient demographics, treatment received, and molecular characteristics were obtained from the Electronic Patient Record (EPR). Tumor molecular characteristics were analyzed using the OnkoSight Advanced CNS NGS panel. Statistical analyses were performed to develop a prognostic model for glioblastoma recurrence and estimate survival rates. Among the patients, 65.4% had no recurrence, with a mean age of 63 years. No gender or BMI differences were observed, but ages <60 years were associated with recurrence. Radiological findings showed no significant differences in tumor size, necrosis, site, or focality. In multivariate analysis, the female gender, obesity, old age (>60 years), or bifocal tumors were associated with decreased glioblastoma recurrence. However, factors like tumor site, size, necrosis, <i>MGMT</i> promoter methylation, and <i>EGFR</i> alteration showed no significant association with recurrence. Median survival was 12 months, with older age significantly associated with shorter survival. Tumor sizes >4 cm showed shorter survival trends but not statistically significantly. Patients who lived longer experienced more tumor recurrence incidents. Standard or non-standard treatments were associated with longer median survival compared to no treatment. Our findings provide insights into factors influencing glioblastoma recurrence and survival. Age, gender, and tumor characteristics play pivotal roles in recurrence. Understanding these factors could aid in optimizing treatment strategies and improving patient outcomes. However, further multicentric investigations are needed to validate these findings. This study emphasizes the importance of considering biological and radiological factors in clinical decision-making for glioblastoma cases.https://www.mdpi.com/2673-5261/5/4/35glioblastoma recurrenceIDH-wild type |
| spellingShingle | Ahmed Bendari Sunder Sham Hamed Hammoud Oana Vele Brett Baskovich David Huang Alaa Bendari Rachel Saks Reham Al-Refai Tasneem Bendari Layth Kataw Fnu Kiran Fnu Anjali Sanjay Kirshan Kumar Manju Harshan “Comprehensive Analysis of Factors Influencing Recurrence and Survival in Glioblastoma: Implications for Treatment Strategies”: A Single Center Study Journal of Molecular Pathology glioblastoma recurrence IDH-wild type |
| title | “Comprehensive Analysis of Factors Influencing Recurrence and Survival in Glioblastoma: Implications for Treatment Strategies”: A Single Center Study |
| title_full | “Comprehensive Analysis of Factors Influencing Recurrence and Survival in Glioblastoma: Implications for Treatment Strategies”: A Single Center Study |
| title_fullStr | “Comprehensive Analysis of Factors Influencing Recurrence and Survival in Glioblastoma: Implications for Treatment Strategies”: A Single Center Study |
| title_full_unstemmed | “Comprehensive Analysis of Factors Influencing Recurrence and Survival in Glioblastoma: Implications for Treatment Strategies”: A Single Center Study |
| title_short | “Comprehensive Analysis of Factors Influencing Recurrence and Survival in Glioblastoma: Implications for Treatment Strategies”: A Single Center Study |
| title_sort | comprehensive analysis of factors influencing recurrence and survival in glioblastoma implications for treatment strategies a single center study |
| topic | glioblastoma recurrence IDH-wild type |
| url | https://www.mdpi.com/2673-5261/5/4/35 |
| work_keys_str_mv | AT ahmedbendari comprehensiveanalysisoffactorsinfluencingrecurrenceandsurvivalinglioblastomaimplicationsfortreatmentstrategiesasinglecenterstudy AT sundersham comprehensiveanalysisoffactorsinfluencingrecurrenceandsurvivalinglioblastomaimplicationsfortreatmentstrategiesasinglecenterstudy AT hamedhammoud comprehensiveanalysisoffactorsinfluencingrecurrenceandsurvivalinglioblastomaimplicationsfortreatmentstrategiesasinglecenterstudy AT oanavele comprehensiveanalysisoffactorsinfluencingrecurrenceandsurvivalinglioblastomaimplicationsfortreatmentstrategiesasinglecenterstudy AT brettbaskovich comprehensiveanalysisoffactorsinfluencingrecurrenceandsurvivalinglioblastomaimplicationsfortreatmentstrategiesasinglecenterstudy AT davidhuang comprehensiveanalysisoffactorsinfluencingrecurrenceandsurvivalinglioblastomaimplicationsfortreatmentstrategiesasinglecenterstudy AT alaabendari comprehensiveanalysisoffactorsinfluencingrecurrenceandsurvivalinglioblastomaimplicationsfortreatmentstrategiesasinglecenterstudy AT rachelsaks comprehensiveanalysisoffactorsinfluencingrecurrenceandsurvivalinglioblastomaimplicationsfortreatmentstrategiesasinglecenterstudy AT rehamalrefai comprehensiveanalysisoffactorsinfluencingrecurrenceandsurvivalinglioblastomaimplicationsfortreatmentstrategiesasinglecenterstudy AT tasneembendari comprehensiveanalysisoffactorsinfluencingrecurrenceandsurvivalinglioblastomaimplicationsfortreatmentstrategiesasinglecenterstudy AT laythkataw comprehensiveanalysisoffactorsinfluencingrecurrenceandsurvivalinglioblastomaimplicationsfortreatmentstrategiesasinglecenterstudy AT fnukiran comprehensiveanalysisoffactorsinfluencingrecurrenceandsurvivalinglioblastomaimplicationsfortreatmentstrategiesasinglecenterstudy AT fnuanjali comprehensiveanalysisoffactorsinfluencingrecurrenceandsurvivalinglioblastomaimplicationsfortreatmentstrategiesasinglecenterstudy AT sanjaykirshankumar comprehensiveanalysisoffactorsinfluencingrecurrenceandsurvivalinglioblastomaimplicationsfortreatmentstrategiesasinglecenterstudy AT manjuharshan comprehensiveanalysisoffactorsinfluencingrecurrenceandsurvivalinglioblastomaimplicationsfortreatmentstrategiesasinglecenterstudy |